Neurons expressing somatostatin receptor 5 (SSTR5) represent a key population in the hypothalamic and pituitary regulation of hormone secretion, metabolism, and neuronal function. SSTR5 is one of five somatostatin receptor subtypes (SSTR1-5) that mediate the effects of somatostatin (SST), a widely expressed neuropeptide with potent inhibitory effects on hormone release and neuronal excitability.
¶ Gene and Protein
| Property |
Value |
| Gene Symbol |
SSTR5 |
| Chromosomal Location |
16p13.3 |
| Protein Name |
Somatostatin receptor 5 |
| UniProt ID |
P78540 |
| Protein Class |
G protein-coupled receptor (GPCR), Class A |
The SSTR5 gene encodes a 363-amino acid GPCR that couples primarily to Gi/o proteins, inhibiting adenylate cyclase and reducing neuronal excitability.
SSTR5 has the typical seven transmembrane domain structure of GPCRs:
- N-terminal extracellular domain: Ligand binding
- Transmembrane domains (7): TM1-TM7
- Extracellular loops (3): Ligand recognition
- Intracellular loops (3): G protein coupling
- C-terminal tail: Desensitization and internalization
Key features:
- Highest affinity for somatostatin-28 over SST-14
- Distinct binding pocket compared to other SSTRs
- Palmitoylation site in C-terminal tail
SSTR5 is expressed in several brain regions:
- Hypothalamus: Arcuate nucleus, paraventricular nucleus, preoptic area
- Cerebral cortex: Layer 2/3 and layer 5 pyramidal neurons
- Pituitary gland: Anterior and intermediate lobe
- Thalamus: Midline nuclei
- Amygdala: Central and basolateral nuclei
- Hippocampus: CA1-CA3 regions, dentate gyrus
- Brainstem: Dorsal raphe, locus coeruleus
SSTR5 neurons are crucial for hormone control:
- Growth hormone regulation: Inhibits GH secretion from pituitary
- Thyroid function: Modulates TSH release
- Reproductive hormones: Influences LH/FSH
- Prolactin inhibition: Reduces prolactin secretion
¶ Food Intake and Energy Balance
- Anorexigenic signaling: Suppresses appetite
- Energy expenditure: Increases metabolic rate
- Glucose homeostasis: Modulates insulin secretion
- Body weight regulation: Long-term energy balance
- Inhibitory modulation: Reduces neuronal firing
- Synaptic transmission: Modulates excitatory synapses
- Neuroprotection: Anti-excitotoxic effects
- Oscillation regulation: Influences neuronal rhythms
- Learning and memory: Hippocampal SSTR5 in memory
- Mood regulation: Depression and anxiety
- Pain modulation: Analgesic effects of SSTR5
Involvement:
- SSTR5 expression altered in AD brain
- Relationship to somatostatin deficits in AD
- Therapeutic potential of SSTR5 modulation
- Cognitive enhancement strategies
Mechanisms:
- Amyloid-beta interactions
- Cholinergic system modulation
- Neuroprotective signaling
Involvement:
- Altered SSTR5 in basal ganglia
- Motor symptom modulation
- Levodopa-induced dyskinesias
- Non-motor symptoms
Diabetes:
- SSTR5 in pancreatic beta cells
- Insulin secretion modulation
- Therapeutic targeting for diabetes
- Glucose homeostasis
Obesity:
- SSTR5 agonists for weight loss
- Appetite suppression
- Metabolic syndrome treatment
Involvement:
- SSTR5 in pituitary adenomas
- Acromegaly treatment (octreotide, lanreotide)
- Tumor imaging (SSTR scintigraphy)
- Therapeutic targeting
Involvement:
- SSTR5 in mood regulation
- SSRIs affect SSTR5 expression
- Therapeutic potential
- Biomarker potential
SSTR5 activates multiple intracellular cascades:
- Gi/o protein signaling: Inhibition of adenylate cyclase
- MAPK pathway: ERK1/2 activation
- PLC pathway: Modulation of calcium
- PI3K/Akt: Cell survival signaling
- SSTR1-SSTR4: Can form heterodimers
- Dopamine receptors: Cross-talk in pituitary
- Ghrelin receptor: Metabolic interactions
-
SSTR5 agonists:
- Octreotide, lanreotide (approved)
- Pasireotide (SSTR5-selective)
- New generations in development
-
SSTR5 antagonists:
- Potential for cognitive enhancement
- Depression applications
-
Multireceptor ligands:
- Pan-somatostatin analogs
- SSTR2/5 selective compounds
- Acromegaly: First-line treatment
- Neuroendocrine tumors: Therapeutic targeting
- Cushing's disease: Pituitary-directed therapy
- Cognitive disorders: SSTR5 modulators
- SSTR5 expression as tumor marker
- Imaging with radiolabeled somatostatin analogs
- Circuit mapping: Defining SSTR5 neuron populations
- Optogenetics: Manipulating SSTR5 circuits
- Single-cell transcriptomics: SSTR5 neuron heterogeneity
- Drug discovery: Brain-penetrant SSTR5 modulators
- SSTR5 in neuroendocrine function (2019)
- Somatostatin receptors in brain (2020)
- SSTR5 and pituitary tumors (2018)
- Somatostatin in Alzheimer's disease (2019)
- SSTR5 agonists in diabetes (2021)
- Somatostatin and cognitive function (2020)
- Pan-somatostatin analogs for neuroendocrine tumors (2019)
- SSTR5 signaling mechanisms (2017)